Mizuki Takahashi

ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 9

Top Venues

Journal of medicinal chemistry

RSC medicinal chemistry

FEBS letters

Molecular cancer therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Naoki Kuki, David Lee Walmsley, Kazuo Kanai, Sho Takechi, Masao Yoshida, Ryo Murakami, Kohei Takano, Yuichi Tominaga, Mizuki Takahashi, Shuichiro Ito, Naoki Nakao, Hayley Angove, Lisa M Baker, Edward Carter, Pawel Dokurno, Loic Le Strat, Alba T Macias, Carrie-Anne Molyneaux, James B Murray, Allan E Surgenor, Tomoaki Hamada, Roderick Eliot Hubbard
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase. RSC medicinal chemistry 14 (12) (2023)
Naoki Kuki, David Lee Walmsley, Kazuo Kanai, Sho Takechi, Masao Yoshida, Ryo Murakami, Kohei Takano, Yuichi Tominaga, Mizuki Takahashi, Shuichiro Ito, Naoki Nakao, Hayley Angove, Lisa M Baker, Edward Carter, Pawel Dokurno, Loic Le Strat, Alba T Macias, Carrie-Anne Molyneaux, James B Murray, Allan E Surgenor, Tomoaki Hamada, Roderick Eliot Hubbard
A covalent fragment-based strategy targeting a novel cysteine to inhibit activity of mutant EGFR kinase. RSC medicinal chemistry 14 (12) (2023)
Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato, Megumi Goto, Genzui Setsu, Kentaro Ito, Kawori Kihara, Mutsumi Kuroha, Takashi Kohno, Hideaki Ogiwara, Takeshi Isoyama, Yuichi Tominaga, Saito Higuchi, Hiroyuki Naito
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of medicinal chemistry (2022)
Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato, Megumi Goto, Genzui Setsu, Kentaro Ito, Kawori Kihara, Mutsumi Kuroha, Takashi Kohno, Hideaki Ogiwara, Takeshi Isoyama, Yuichi Tominaga, Saito Higuchi, Hiroyuki Naito
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of medicinal chemistry 66 (1) (2022)
Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato, Megumi Goto, Genzui Setsu, Kentaro Ito, Kawori Kihara, Mutsumi Kuroha, Takashi Kohno, Hideaki Ogiwara, Takeshi Isoyama, Yuichi Tominaga, Saito Higuchi, Hiroyuki Naito
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of medicinal chemistry 66 (1) (2022)
Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato, Megumi Goto, Genzui Setsu, Kentaro Ito, Kawori Kihara, Mutsumi Kuroha, Takashi Kohno, Hideaki Ogiwara, Takeshi Isoyama, Yuichi Tominaga, Saito Higuchi, Hiroyuki Naito
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of medicinal chemistry (2022)
Ryutaro Kanada, Yoshiko Kagoshima, Takashi Suzuki, Akifumi Nakamura, Hideaki Funami, Jun Watanabe, Masayoshi Asano, Mizuki Takahashi, Osamu Ubukata, Kanae Suzuki, Tomoya Aikawa, Kazumi Sato, Megumi Goto, Genzui Setsu, Kentaro Ito, Kawori Kihara, Mutsumi Kuroha, Takashi Kohno, Hideaki Ogiwara, Takeshi Isoyama, Yuichi Tominaga, Saito Higuchi, Hiroyuki Naito
Discovery of DS-9300: A Highly Potent, Selective, and Once-Daily Oral EP300/CBP Histone Acetyltransferase Inhibitor. Journal of medicinal chemistry 66 (1) (2022)
Mizuki Takahashi, Osamu Ubukata, Tsuyoshi Homma, Yusuke Asoh, Masatoshi Honzumi, Noriyuki Hayashi, Keiji Saito, Hiroyuki Tsuruoka, Kazumasa Aoki, Hiroyuki Hanzawa
Crystal structure of the mineralocorticoid receptor ligand-binding domain in complex with a potent and selective nonsteroidal blocker, esaxerenone (CS-3150). FEBS letters 594 (10) (2020)
René Bartz, Keisuke Fukuchi, Toshiaki Ohtsuka, Tanja Lange, Katrin Gruner, Ichiro Watanabe, Shinko Hayashi, Yoko Oda, Reimi Kawaida, Hironobu Komori, Yoshinori Kashimoto, Peter Wirtz, Jan-Peter A Mayer, Mauricio Redondo-Müller, Shuntaro Saito, Mizuki Takahashi, Hiroyuki Hanzawa, Emi Imai, Alberto Martinez, Masaharu Hanai, Dieter Häussinger, Roger W Chapman, Toshinori Agatsuma, Johannes Bange, Reimar Abraham
Preclinical Development of U3-1784, a Novel FGFR4 Antibody Against Cancer, and Avoidance of Its On-target Toxicity. Molecular cancer therapeutics 18 (10) (2019)

Mizuki Takahashi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Mizuki Takahashi